BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 29193269)

  • 1. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan.
    Akuta N; Kawamura Y; Arase Y; Suzuki F; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Ikeda K; Kumada H
    Gut Liver; 2016 May; 10(3):437-45. PubMed ID: 26610348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease.
    Koo BK; Joo SK; Kim D; Lee S; Bae JM; Park JH; Kim JH; Chang MS; Kim W
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2592-2599.e10. PubMed ID: 32062042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.
    Busca C; Arias P; Sánchez-Conde M; Rico M; Montejano R; Martín-Carbonero L; Valencia E; Moreno V; Bernardino JI; Olveira A; Abadía M; González-García J; Montes ML
    Front Pharmacol; 2022; 13():905126. PubMed ID: 36110512
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
    Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
    Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients.
    Tai CM; Huang CK; Tu HP; Hwang JC; Yeh ML; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
    Medicine (Baltimore); 2016 Mar; 95(12):e3120. PubMed ID: 27015186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation.
    Míková I; Neřoldová M; Hubáček JA; Dlouhá D; Jirsa M; Honsová E; Sticová E; Lánská V; Špičák J; Trunečka P
    Transplantation; 2020 Mar; 104(3):526-534. PubMed ID: 31356578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.